"text","label","instanceType","uuid:ID","id","description","name"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","","Objective","9b058e1e-cb3c-431d-bcbf-9bfea952d557","Objective_1","Main objective","OBJ1"
"To document the safety profile of the xanomeline TTS.","","Objective","bdb8d3e5-ca78-488c-906a-8b476575bfb0","Objective_2","Safety","OBJ2"
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","","Objective","9080f3dc-d264-4432-a8da-23444ec682b9","Objective_3","Behaviour","OBJ3"
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","","Objective","711d7c8b-36ab-4ca6-ad92-77876fde64bd","Objective_4","","OBJ4"
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","","Objective","a2c0bb37-934a-4f4a-90bf-9dba51dc1a05","Objective_5","","OBJ5"
"To assess the treatment response as a function of Apo E genotype.","","Objective","5d8de63f-0536-478d-8434-947c7f0067d9","Objective_6","","OBJ6"
